Endo Announces Effectiveness of Form S-1 Registration Statement for Existing Shares
MALVERN, Pa., July 31, 2024 /PRNewswire/ — Endo, Inc. (OTCQX: NDOI) (“Endo” or the “Company”), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared effective the Company’s registration statement on Form S-1 related to the registration for resale of certain existing shares of the Company’s common stock held by current shareholders (the “Registration Statement”). The Company filed the Registration Statement with the goal of providing greater liquidity to shareholders and creating an orderly trading market in its common stock.
Related news for (NDOI)
- Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting
- Endo Completes International Pharmaceuticals Business Divestiture
- Endo Champions Men’s Health Month with Education, Awareness, and Outreach
- Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration
- Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance